Small molecules. Big impact.
Sagacity Pharmaceuticals is dedicated to developing medicines for the prevention of Alzheimer’s Disease.
Currently 5.7million Alzheimer’s Disease (AD) patients are recognized in the US, a number expected to reach 14 million by 2050. This corresponds to expected costs of just over 2trillion USD (forecast for 2050). Correspondently, the market for AD therapeutics is expected to reach 6.4billion USD in 2025. We have learned that AD therapeutics must be administrated before significant brain damage has occurred. Thus, preventive strategies are needed.
Sagacity is focused on developing drugs for the prevention of Alzheimer’s Disease. This requires a safe drug that gets to the brain and is of low burden to patients in terms of both cost and application. In our primary drug development program, small molecules blocking Tau aggregation will be optimized to lead stage. Upon development of our lead compounds, we will enter pre-clinical development, becoming investor-ready for more significant funding to complete Phase I/II studies in healthy persons at high risk of AD, as defined by biomarkers. Using a proprietary assay to screen the J&J compound library, we have obtained first-line hits, giving us the green light to proceed with our large-scale screen. At this time, we are working with J&J to spin out this early phase program, that will serve as the cornerstone of our portfolio.
Sagacity is an entrepreneurial team of young pharmaceutical professionals with complementary expertise. Leveraging our experience in a big pharma environment we combine this with the dynamics of a lean, virtual company. Sagacity is led by Karen E. Malone; a proven team leader with strong business acumen and extensive experience in biomarker studies for AD and novel first-in-class drugs. Drug development is driven by Jarek Juraszek; a drug discovery, structural biology and bioinformatics scientist. Jarek has been involved in developing treatments for several targets previously perceived to be “undruggable”, such as PCSK9. The team is completed by Ashraf Hachhouch, a business developer, with a background in biomedical sciences. He combines his work on Public-Private Partnership financing to support building teams and companies.
In our primary drug development program for Tau aggregation inhibitors, compounds will be optimized to lead stage. Upon selection of our lead compounds, we will enter pre-clinical development, becoming investor-ready for more significant funding to complete Phase I/II studies in healthy persons at high risk of AD, as defined by biomarkers. To reach our next developmental milestone – completion of the hit-to-lead optimization- an investment of 600.000 is needed.
The Sagacity team consists of Karen Malone, Ashraf Hackhouch and Jarek Juraszek.
- Venture Challenge Spring 2018, BioBusiness Summer School 2016, Finance for Pharma Growth course Fall 2017 VU, Webit Festival 2018 Founder’s Games
- Karen Malone | email@example.com